# Suven Life Sciences (NSE: SUVEN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SUVEN · Pivot · prices to 21 Oct 2026

Suven Life Sciences (NSE: SUVEN) closed at ₹281.40 on 21 Oct 2026. With a market capitalisation of ₹8,208 Cr, it ranks 617th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −146.1% in FY25. Over the past year the share price has risen 39.0%. Its 52-week range is ₹124.11 (24 Mar 2026) to ₹403.35 (1 Sep 2026); the last close is 30.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4 Cr (+90.9% year on year) and net profit −₹128 Cr, on a consolidated basis. Promoters held 65.47% of the company as of 8 Jul 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹281.40 |
| Market cap | ₹8,208 Cr |
| ROE | −146.1% (FY25) |
| ROCE | −143.9% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹403.35 (1 Sep 2026) |
| 52-week low | ₹124.11 (24 Mar 2026) |
| 1-year return | +39.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹4 Cr | +90.9% | −₹128 Cr | — | −₹4.84 |
| Q4 FY26 | ₹2 Cr | +3.4% | −₹46 Cr | — | −₹2.02 |
| Q3 FY26 | ₹3 Cr | +74.5% | −₹102 Cr | — | −₹4.55 |
| Q2 FY26 | ₹1 Cr | −64.2% | −₹77 Cr | — | −₹3.48 |
| Q1 FY26 | ₹2 Cr | +85.1% | −₹52 Cr | — | −₹2.36 |
| Q4 FY25 | ₹1 Cr | — | −₹44 Cr | — | −₹2.02 |
| Q3 FY25 | ₹2 Cr | −34.3% | −₹39 Cr | — | −₹1.79 |
| Q2 FY25 | ₹3 Cr | −16.0% | −₹50 Cr | — | −₹2.27 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹7 Cr | −₹161 Cr |
| FY24 | ₹12 Cr | −₹105 Cr |
| FY23 | ₹14 Cr | −₹118 Cr |
| FY22 | ₹12 Cr | −₹122 Cr |
| FY21 | ₹13 Cr | −₹72 Cr |
| FY20 | ₹14 Cr | −₹94 Cr |

## Shareholding (8 Jul 2026)

- Promoters: 65.47%
- Foreign institutions: 0.48%
- Domestic institutions: 2.73%
- Non-institutions: 31.32%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Strides Pharma Science](https://app.pivotnow.in/stock/STAR) | ₹1,019.90 | ₹9,401 Cr | 16.9 | — |
| [Yatharth Hospital & Trauma Care Services](https://app.pivotnow.in/stock/YATHARTH) | ₹968.00 | ₹9,327 Cr | 53.1 | — |
| [Healthcare Global Enterprises](https://app.pivotnow.in/stock/HCG) | ₹570.00 | ₹8,510 Cr | — | — |
| [Sanofi Consumer Healthcare India](https://app.pivotnow.in/stock/SANOFICONR) | ₹3,473.40 | ₹7,999 Cr | 31 | — |
| [Aarti Pharmalabs](https://app.pivotnow.in/stock/AARTIPHARM) | ₹835.00 | ₹7,572 Cr | 43.4 | — |
| [Thyrocare Technologies](https://app.pivotnow.in/stock/THYROCARE) | ₹469.95 | ₹7,480 Cr | 46.1 | — |

## Questions and answers

### What is the share price of Suven Life Sciences today?

Suven Life Sciences (NSE: SUVEN) last closed at ₹281.40 on 21 Oct 2026. Its 52-week high is ₹403.35 and its 52-week low is ₹124.11.

### What is the market cap of Suven Life Sciences?

Suven Life Sciences' market capitalisation is ₹8,208 Cr (₹8,208 Cr) at the 19 Oct 2026 close, ranking 617th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Suven Life Sciences?

Return on equity was −146.1% in FY25 and return on capital employed was −143.9% in FY25 (consolidated figures).

### Is Suven Life Sciences a debt-free company?

Suven Life Sciences is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Suven Life Sciences' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Suven Life Sciences reported revenue of ₹4 Cr, +90.9% year on year, and net profit of −₹128 Cr.

### How has Suven Life Sciences stock performed over the last year?

Suven Life Sciences' share price has risen 39.0% over the past year, −14.1% over three months and −17.5% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Suven Life Sciences?

As of 8 Jul 2026: promoters 65.47%, foreign institutions 0.48%, domestic institutions 2.73%, non-institutions 31.32%.

### Who are Suven Life Sciences' competitors?

The listed Pharma & Healthcare companies closest to Suven Life Sciences by market cap are Strides Pharma Science, Yatharth Hospital & Trauma Care Services, Healthcare Global Enterprises, Sanofi Consumer Healthcare India, Aarti Pharmalabs and Thyrocare Technologies.

### Is Suven Life Sciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Suven Life Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUVEN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.